Search
Idecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
Amphotericin B
go.drugbank.com/drugs/DB00681ApprovedInvestigationalHistoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by
Oxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigational[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990]
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize t...
Ketorolac
go.drugbank.com/drugs/DB00465ApprovedInvestigationalKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across ma...
Interferon alfa
go.drugbank.com/drugs/DB05258ApprovedInvestigationalWithdrawnInterferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography.
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma